We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Inovium Ovarian Rejuvenation Trials

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03178695
Recruitment Status : Completed
First Posted : June 7, 2017
Last Update Posted : April 20, 2020
Information provided by (Responsible Party):
Ascendance Biomedical

Tracking Information
First Submitted Date  ICMJE April 19, 2017
First Posted Date  ICMJE June 7, 2017
Last Update Posted Date April 20, 2020
Actual Study Start Date  ICMJE June 1, 2017
Actual Primary Completion Date May 1, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 5, 2017)
  • Positive IVF [ Time Frame: 12 months ]
    Following the initial Ovarian Rejuvenation Treatment, subjects will undergo IVF treatment to test the efficacy of the Protocol for fertility outcomes, as per trial protocols.
  • Positive Pregnancy and Conception [ Time Frame: 12 months ]
    Following completion of trial protocols, patients will conduct ongoing post-treatment follow-up with trial staff for recording progress of all ongoing pregnancies and conceptions, via post-treatment correspondence.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 5, 2017)
  • Resumption of Menses [ Time Frame: 12 months ]
    With Premature Ovarian Failure and natural menopause the normal menstrual cycle is disrupted and normal menses does not occur. Patients will monitor for resumption of menses.
  • Changes in Hormone Levels [ Time Frame: 12 months ]
    Changes in hormonal levels toward normal ranges. Hormones may include FSH/LH; Estradiol/ progesterone;Inhibin; Anti- Mullerian Hormone
  • Changes in Egg Quality [ Time Frame: 12 months ]
    Using Pre-Implantation Genetic Screening, the trials will study the changes to egg quality of all eggs generated as a result of the treatment. A comparison group of patients who have received standard IVF treatment without the Inovium Ovarian Rejuvenation Treatment will be used to study this outcome.
  • Changes in Health Outcomes [ Time Frame: 12 months ]
    Changes in overall health levels will be studied. A comparison group of patients who have received standard IVF treatment without the Inovium Ovarian Rejuvenation Treatment will be used to study this outcome. All patient data collected as described in the other outcomes will be used in this comparison.
  • Duration of Identified Benefits of Treatment [ Time Frame: 12 months ]
    The duration of effects will be studied, in order to identify a frequency of treatment necessary to sustain positive health and fertility outcomes.
  • Changes in Menopausal Symptoms [ Time Frame: 12 months ]
    A before-and-after questionnaire will be administered to collect patient personal experience data regarding changes in menopausal symptoms.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Inovium Ovarian Rejuvenation Trials
Official Title  ICMJE Autologous Platelet-Rich Plasma (PRP) Infusions and Biomarkers of Ovarian Rejuvenation and Aging Mitigation
Brief Summary The Inovium Ovarian Rejuvenation Treatment is a PRP-based autologous treatment used in combination with a stimulated IVF sequence and Pre-Implantation Genetic Screening to treat infertility in women experiencing menopause, perimenopause, and premature ovarian failure.
Detailed Description

This research extends earlier work conducted by Inovium associates in Athens, Greece who demonstrated efficacy of intraovarian injection of autologous PRP for resumption of menses, hormone stabilization, and conception after IVF in multiple women following PRP+natural cycle IVF (i.e., without gonadotropin stimulation). The use of stimulation (gonadotropins) and targeted pre- and posttreatment hormone monitoring during this clinical trial aims to characterize more fully the transition from PRP dosing, embryogenesis, IVF and conception.

The current study seeks to describe how PRP works to rejuvenate immune system and ovarian stem cells, restore menses, provide hormone stability, and generate successful IVF sequences and conceptions. The quality of all embryos generated will be studied via PGS, with the goal of generating euploid embryos. Hormone stability and biomarkers of aging will also be evaluated to understand the extent of any observed benefits, and to estimate how long such effects may be sustained with a single PRP treatment.

Autologous activated PRP used in this clinical study is isolated from patient derived (blood) samples collected on-site, using FDA-approved Regenlab [Lausanne, Switzerland] BCT-1 PRP Kit and RegenLab Drucker Centrifuge (FDA 510(k)-Approval #BK110061; ISO#13485).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
A study group receives the intervention, which is compared in terms of efficacy against a matched group of control patients.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Perimenopausal Disorder
  • Menopause
  • Menopause, Premature
  • Menopause Related Conditions
  • Menopause Premature Symptomatic
  • Menopause Premature Asymptomatic
  • Premature Ovarian Failure
  • Premature Ovarian Failure, Familial
  • Premature Ovarian Failure 2A
  • Premature Ovarian Failure 3
  • Premature Ovarian Failure 4
  • Premature Ovarian Failure 1
  • Premature Ovarian Failure 5
  • Premature Ovarian Failure 6
  • Premature Ovarian Failure 7
  • Premature Ovarian Failure 9
  • Premature Ovarian Failure 8
  • Infertility
  • Infertility, Female
  • Infertility Unexplained
Intervention  ICMJE Other: Autologous PRP injection into human ovarian tissue
Using FDA-approved equipment, blood plasma is received from participant, isolated/enriched into PRP, and infused into the ovaries under transvaginal ultrasound guidance.
Study Arms  ICMJE
  • Experimental: Treatment Group
    PRP is freshly isolated from patients with diminished ovarian reserve as determined by at least one prior IVF cycle canceled for poor follicular recruitment response, or estimated by serum AMH and/or FSH, no menses for ≥1 year. Immediately following substrate isolation and activation with calcium gluconate, approximately 5 mL of autologous PRP is injected into each ovary under direct transvaginal sonogram guidance. AMH, FSH, and serum estradiol data will be recorded at 2wk intervals post-PRP and compared to baseline (pre-PRP) values.
    Intervention: Other: Autologous PRP injection into human ovarian tissue
  • No Intervention: Comparison Group
    Data collected from all patients in the Treatment Group will be compared to a dataset compiled from 25 - 50 women of similar age having received like treatment via IVF and gonadotropin stimulation for positive fertility outcomes in past clinical work at the Center for Advanced Genetics, as a comparison model and substitute control group. The purpose of this comparison will be to determine overall efficacy of the Inovium Ovarian Rejuvenation Treatment as separated from the standard efficacy rates of CAG-established IVF processes and gonadotropins used in the trial.
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 18, 2018)
Original Estimated Enrollment  ICMJE
 (submitted: June 5, 2017)
Actual Study Completion Date  ICMJE May 1, 2018
Actual Primary Completion Date May 1, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Signed and dated informed consent
  • Women over the age of 35
  • Primary or secondary amenorrhea at least for 3-6 months
  • Presence of at least one ovary
  • Agree to report any pregnancy to the research staff immediately.
  • Willing and able to comply with study requirements.
  • Willing to receive IVF to get pregnant as part of the experimental protocol.

Exclusion Criteria:

  • Men will be excluded from the study.
  • Current or previous IgA deficiency
  • Current or previous premature ovarian failure due to a genetic origin, such as Turner's Syndrome or chromosomal abnormality
  • Current or previous great injuries or adhesions to the pelvis or ovaries
  • Current and ongoing pregnancy
  • Current and ongoing anticoagulant use for which plasma infusion appears contraindicated
  • Current and ongoing major Mental health disorder that precludes participation in the study
  • Current and ongoing active substance abuse or dependence
  • Current and ongoing gynecological or non-gynecological cancer
  • Current and ongoing chronic pelvic pain
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Gender Based Eligibility: Yes
Gender Eligibility Description: Men are not eligible to participate in the trials.
Ages  ICMJE 35 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT03178695
Other Study ID Numbers  ICMJE 882388
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: All requests and considerations for data sharing with individual and institutional researchers will be reviewed by the members of the Inovium Trials' Scientific Advisory Board and Primary Investigator.
Current Responsible Party Ascendance Biomedical
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Ascendance Biomedical
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: E Scott Sills, MD PhD Center for Advanced Genetics (CAG)
PRS Account Ascendance Biomedical
Verification Date April 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP